Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy

Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy Publisher

Fakhari A¹ ; Jalilian AR² ; Yousefnia H² ; Joharidaha F² ; Mazidi M² ; Khalaj A¹

Show Affiliations

1. Tehran University of Medical Sciences, Tehran, Iran
2. Radiopharmaceutical Research and Development Lab (RRDL), Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran

Source: Journal of Radioanalytical and Nuclear Chemistry Published:2015

Abstract

In this work 166Ho labeled (3-amino-1-hydroxypropane-1,1-di-yl)-bis-(phosphonate) (166Ho-PMD) complex was prepared successfully at optimized conditions with acceptable radiochemical purity, stability and significant hydroxyapatite absorption. The biodistribution of 166Ho-PMD up to 48 h demonstrated significant bone uptake ratios at all time intervals but not superior to 166Ho-EDTMP. © 2014, Akademiai Kiado, Budapest, Hungary.

Related Docs

1. Radiolabeling and Evaluation of Two 177Lu-Labeled Bis-Phosphonates, Iranian Journal of Nuclear Medicine (2015)

2. Production, Quality Control, Biodistribution Assessment and Preliminary Dose Evaluation of 166Ho-Alendronate As a Bone Marrow Ablative Agent, Radiochimica Acta (2015)

3. An Impressive Approach in Nuclear Medicine: Theranostics, PET Clinics (2021)

4. Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain, Journal of Clinical Medicine (2020)

Experts (# of related papers)

View all Related Experts

Nasim Vahidfar (1)

Mehdi Shafee Ardestani (1)

Style	Citing Format
MLA	Fakhari A, et al.. "Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy." Journal of Radioanalytical and Nuclear Chemistry, vol. 303, no. 1, 2015, pp. 743-750.
APA	Fakhari A, Jalilian AR, Yousefnia H, Joharidaha F, Mazidi M, Khalaj A (2015). Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy. Journal of Radioanalytical and Nuclear Chemistry, 303(1), 743-750.
Chicago	Fakhari A, Jalilian AR, Yousefnia H, Joharidaha F, Mazidi M, Khalaj A. "Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy." Journal of Radioanalytical and Nuclear Chemistry 303, no. 1 (2015): 743-750.
Harvard	Fakhari A et al. (2015) 'Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy', Journal of Radioanalytical and Nuclear Chemistry, 303(1), pp. 743-750.
Vancouver	Fakhari A, Jalilian AR, Yousefnia H, Joharidaha F, Mazidi M, Khalaj A. Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy. Journal of Radioanalytical and Nuclear Chemistry. 2015;303(1):743-750.
BibTex	@article{ author = {Fakhari A and Jalilian AR and Yousefnia H and Joharidaha F and Mazidi M and Khalaj A}, title = {Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy}, journal = {Journal of Radioanalytical and Nuclear Chemistry}, volume = {303}, number = {1}, pages = {743-750}, year = {2015} }
RIS	TY - JOUR AU - Fakhari A AU - Jalilian AR AU - Yousefnia H AU - Joharidaha F AU - Mazidi M AU - Khalaj A TI - Development of 166Ho-Pamidronate for Bone Pain Palliation Therapy JO - Journal of Radioanalytical and Nuclear Chemistry VL - 303 IS - 1 SP - 743 EP - 750 PY - 2015 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract